- First fill split supply for oral oncology products
- Strattera
- Non-sedating antihistamine coverage re: Allegra OTC
- Generic Tricor
- Prograf - Coverage Considerations
- Colcrys
- Pradaxa (dabigatran)
- Solodyn, generics and add-on dosages
- At-Risk Generic Crestor?
- Gilenya -- $48k per year?
- Triptan Step Care Therapy
- Avandia formulary management post FDA advisory board
- Piroxicam
- Step therapy for ARBs
- Effexor XR
- Off-label uses for Cellcept and Prograf
- Effient metabolism issues
- ampyra
- Subutex & Suboxone policies
- Pramipexole - Mirapex
- Vorinostat (Zolinza)
- Adderall XR generic
- Generic Prevacid
- Afinitor sales projections
- Antiviral Coverage for H1N1 (Swine)
- Prevacid 24HR -- Add to Formulary?
- Edluar and Zolpimist coverage
- Pred Forte versus Generic Prednisolone Acetate 1% Ocular suspension
- Xenazine policy criteria
- Anticipated impact of proposed restrictions on RX APAP combo products
- Generic Wellbutrin XL
- Generic Cellcept
- Arimidex in children
- Emend coverage B vs. D
- Multi-source brand anticonvulsants
- Safety of TriLipix in combo with a statin
- Plavix and PPI interaction
- Symbicort for children
- Coverage of Sancuso
- Duration of therapy for bisphosphonates
- Metoprolol ER shortage
- ARBs for CHF
- Impact of JUPITER data on statin utilization
- Antidepressants for children
- Drugs used in autism
- Lidoderm Patch Criteria
- Criteria for Testosterone Replacement Therapy
- Phase out of albuterol inhalers
- Coverage of daily Cialis
- ADHD drugs for adults
- Renagel/Renvela
- Generic fluticasone ADRs
- Safety of statins
- PDE-5 Inhibitors Post-Prostectomy
- Nimotop UM restrictions
- Offlabel uses of oral contraceptives
- Provigil for cancer-related fatigue
- Comparative reviews of fibromyalgia therapies
- Sedatives/hypnotics and sleep apnea
- Availability of Altocor
- Discontinued Bromfenex
- Lipitor patent
- Bactroban and Altabax for topical MRSA infections
- Chantix in the news
- Sular New Formulation
- How do most plans handle new generics?
- Digitek recall
- Cough avoidance using ARB in asthma
- Cholinesterase inhibitors in brain damage
- Neurontin in fibromyalgia
- Cialis for PAH
- Ambien for long-term use
- Singulair in sarcoidosis
- Safety and efficacy of Celebrex vs Mobic
- Singulair in reactive airway disease/bronchospasm
- Cialis in Raynaud's disease
- Flomax use in urinary retention/bladder or stones
- Lyrica disability data for fibromyalgia
- Previous treatment before Tykerb
- Lyrica in fibromyalgia
- Tamiflu utilization in relation to flu vaccine coverage
- Limits on sedative hypnotics
- Pipeline for antidepressants
- Cholinesterase inhibitor use in children with autism
- Celebrex and inhibition of platelet aggregation
- Lyrica in depression
- Thalomid approval for multiple myeloma
- Cymbalta in non-diabetic neuropathy
- Generic OxyContin
- Neurontin and abuse potential